Pharmaceuticals, Biotechnology and Life Sciences
AstraZeneca and its haematology research and development centre of excellence, Acerta Pharma, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for acalabrutinib for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
Onxeo has sold of two products Sitavig and Loramyc to Vectans Pharma, a private pharmaceutical company which develops and markets innovative therapeutics in oral pathologies.
Transgene has treated the first patient in a Phase 1/2 clinical trial for the combination of Pexa-Vec with Opdivo as a first-line treatment of advanced hepatocellular carcinoma (HCC). The trial will assess the safety and tolerability as well as the anti-tumor activity and efficacy of this immunotherapy combination regimen in up to 36 patients (NCT03071094). This tumour accounts for approximately 75% of liver cancers.
STA Pharmaceutical, a WuXi AppTec group company has merged with WuXi AppTec’s Pharmaceutical Development Services (PDS) division.
STA Pharmaceutical, a WuXi AppTec subsidiary has signed a supply agreement with the oncology-focused biopharmaceutical company, Tesaro, for certain starting and intermediate materials for Zejula (Niraparib).
Cardinal Health has completed the acquisition of Medtronic’s Patient Care, Deep Vein Thrombosis and Nutritional Insufficiency business for $6.1 billion.
David Meek, Chief Executive Officer of Ipsen, said that the company’s performance in the first half of 2017 exceeded expectations, leading to an improved financial outlook for the full year.
Bavarian Nordic has announced an additional worldwide exclusive license and collaboration agreement with Janssen Pharmaceuticals, which grants Janssen the exclusive rights to Bavarian Nordic’s MVA-BN technology for two programs, targeting vaccines against hepatitis B virus (HBV) and the human immunodeficiency virus (HIV-1).
AstraZeneca and Merck on Thursday said that they have made a deal to co-develop and co-commercialise AstraZeneca’s oncology product Lynparza (olaparib) for multiple cancer types. Lynparza is an oral poly ADP ribose polymerase (PARP) inhibitor currently approved for BRCA-mutated ovarian cancer in multiple lines of treatment.
Arix Bioscience has co-led an oversubscribed Series A financing round raising $29 million for PreciThera, a new Arix Group Business focused on developing novel biological therapeutics to treat orphan bone diseases.